Business Wire

Forge Closes Over $150M in Funding, Adds New Investors Amid Another Record-Breaking Quarter

4.5.2021 17:30:00 EEST | Business Wire | Press release

Share

Forge Global, Inc. (“Forge”), the leading global private securities marketplace, announced today that it has received FINRA approval to operate as a single broker dealer with SharesPost, which Forge merged with in 2020, and that it closed an oversubscribed round of more than $150M in new funding. Total funding raised to date exceeds $250M with the latest round including existing investor Deutsche Börse and Forge’s new investors Temasek, Wells Fargo Strategic Capital, LUN Partners Group and others. The continued interest from global strategic and financial investors validates Forge’s leadership position as it continues to develop new, innovative products and services to meet the needs of the private market.

“We’re excited to have these incredible companies partner with Forge as we continue to build the operating system for the private market,” said Forge CEO Kelly Rodriques. “With their support and backing, and the momentum coming from the SharesPost merger, we are in an excellent position to continue to build world-class solutions and bring data, technology and liquidity at scale to the private markets.”

Since inception, Forge has completed more than $9B in transactions in nearly 400 private companies. In the months since its acquisition of SharesPost, the company tallied three consecutive record-breaking quarters including in Q1 2021 when Forge completed 1400 transactions totaling more than $730M of volume.

Forge intends to use the increased funding to continue to expand service offerings in the US and beyond. Jane Atherton, Managing Director, Investment at Temasek International and Paul Hilgers, Managing Director of Deutsche Börse's cash market business, will join Forge’s board.

“The importance of private markets is growing – for companies and investors alike,“ explains Christoph Hansmeyer, Head of Group Strategy & M&A at Deutsche Börse. “Investing in Forge pays testament to our commitment to help companies access liquidity both publicly and privately, and allows global investors to participate in the wealth created in both the public and private markets.”

With more than 642 private unicorn companies globally totaling $2T in collective valuation and with many of those staying private for 10 years or more, unicorn companies are increasingly turning to the private market for liquidity solutions that Forge provides. Global institutions, through their investments in Forge, are signaling increased interest in innovative new products and services that build on the core secondary trading capabilities that the Forge platform delivers.

"The private securities market plays an increasingly important role in today’s financial landscape, and Wells Fargo recognizes the significance of a digital platform like Forge in the ongoing evolution of this marketplace,” said Tom Richardson, Head of Principal Technology Investments at Wells Fargo Strategic Capital. “Forge's liquidity solutions simplify the complexities of private market transactions and introduces further transparency into the price discovery process. We’re excited about the opportunities this brings to our customers and look forward to seeing Forge’s continued growth.”

In February 2021, Forge launched Forge Company Solutions, a comprehensive liquidity solution suite for private, high-growth companies to facilitate custom liquidity programs including executive liquidity, company-sponsored employee liquidity, tender offers and direct listings.

About Forge

Forge serves the complex and emerging needs of the private market ecosystem by forging new connections through our technology, data and expertise. Founded in 2014, the firm empowers investors and shareholders by facilitating liquidity in the private markets. Forge is backed by top Silicon Valley investors and large, global institutions including Deutsche Börse, Temasek, Wells Fargo, BNP Paribas, FT Partners, Draper Associates, Peter Thiel, Munich Re Ventures and LUN Partners Group. . Securities related services are offered through Forge Market, LLC (“Forge Markets”) and SharesPost Financial Corporation (“SPFC”), each of which is a member of FINRA/SIPC and wholly owned subsidiaries of Forge Global, Inc. Transactional information includes trades conducted through SPFC, Forge Markets, and Emerson Equity, LLC (Member FINRA/SIPC and a broker dealer for SharesPost, Inc.) in 2011.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kelsey Quickstad
press@forgeglobal.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye